• PRESS RELEASES

• FINANCIAL FILINGS

July 26, 2010 - Titan receives SBIR grant to investigate long term treatment for Parkinson's disease

July 23, 2010 - Titan reports second quarter 2010 Fanapt® royalty

June 16, 2010 - Probuphine® patent issued by the U.S. Patent and Trademark Office.

May 17, 2010 - Titan Pharmaceuticals announces first quarter 2010 financial results - Conference Call Tomorrow, May 18, 2010

April 24, 2010 - Titan announces completion of re-registration of the company with the securities and exchange commission

April 21, 2010 - Titan provides estimate of upcoming royalty payment

March 30, 2010 - Titan Initiates Confirmatory Phase 3 Study Of Probuphine® In The Treatment Of Opioid Addiction

February 3, 2010 - Titan Pharmaceuticals President Sunil Bhonsle to present at the 12th Annual Bio CEO & Investor Conference Monday, February 8, 2010

January 19, 2010 - Titan Pharmaceuticals files FORM 10 for re-registration of the company with the Securities and Exchange Commission

December 21, 2009 - Titan pharmaceuticals to receive $3 million loan Additional $1 million in equity raised in recent months

November 30, 2009 - Titan Recieves Notice Of Allowance For Probuphine® Patent Application In The Treatment Of Opiate Addiction

October 12, 2009 - Novartis Pharma Acquires Exclusive Rights From Vanda Pharmaceuticals for Commercialization of FANAPT™

October 1, 2009 - Titan announces award of NIH grant for Probuphine®

May 7, 2009 - Titan announces FDA approval of FANAPT™

Dec 15, 2008 - Titan Announces Reductions in Workforce

December 3, 2008 - Titan Announces Board Decision to Delist Common Stock

December 2, 2008 - Titan Pharmaceuticals Announces Reduction in Force

November 19, 2008 - Titan Presents Phase 3 Data for Probuphine®